Sie sind hier
Cordlife is Asia’s largest network of cord blood banks
Celebrating 22 years (in 2024) in business as the largest cord blood banking network in Asia
Cordlife Group Limited (“Cordlife”, together with its subsidiaries, the “Group”), founded in 2001, owns and operates Asia’s largest network of private cord blood banks. The Group is committed to ensuring the health and well-being of both mother and child, amongst others. Listed on the Mainboard of the Singapore Exchange since 2012, the Group is a pioneer in private cord blood banking in Asia. Cordlife has processed and stored more than 400,000 cord blood, cord lining, cord tissue, and placenta stem cell samples, and has extensive transplant experience. With full stem cell banking facilities in six key markets, Cordlife is an industry leader in Singapore, Hong Kong, Indonesia and the Philippines, and one of the top three market leaders in India and Malaysia. Through its majority-owned subsidiary in Malaysia, StemLife Berhad, Cordlife has an indirect stake in Thailand’s largest private cord blood bank, Thai StemLife. In addition to cord blood, cord lining, cord tissue, and placenta banking, Cordlife offers families a comprehensive suite of clinical diagnostics, including non-invasive prenatal testing, paediatric vision screening and newborn metabolic screening. Cordlife strives to ensure reliable quality and is committed to a customer-centric approach. For more information, visit https://cordlife.listedcompany.com/.
Cordlife has transplant experience across Asia
Cordlife has processed and stored more than 400,000 cord blood, cord lining, cord tissue, and placenta stem cell samples.
The Group has made 77 cord blood releases to 21 healthcare institutions in ten different countries, allowing their clients to use their cord blood for transplantation or cellular therapy. Cordlife has also assisted its clients in the release of 21 cord lining and cord tissue samples for medical use. All of the samples processed and stored by Cordlife were used successfully in cellular therapy, which is the ultimate validation of the Group’s processing and storage capabilities.
Over the years, the Group has also grown to offer diagnostics and other healthcare services. This has helped to strengthen their position as a leading company focused on protecting the health of mother and child.
The umbilical cord, once discarded as medical waste after childbirth, is a rich source of readily available stem cells for therapies. Cordlife Group is constantly collaborating with credible researchers and partners to help families live healthier, happier, and longer. Cordlife has published a study with one of their strategic partners, CellResearch Corporation (CRC), on the superior effects of using their patented culture media to extract and accelerate the growth of mesenchymal stromal cells (MSC) from cryopreserved umbilical cord tissue. The study also discussed the numerous advantages of umbilical cord-derived MSCs in the healing of chronic wounds. As the healthcare industry shifts towards a greater focus on early detection and preventive care, umbilical cord-derived MSCs will play an important role in not only treating diseases but also slowing their progression or even delaying their onset entirely. This collaboration validates Cordlife Group’s commitment to being a part of the future of medicine and healthcare to help people live better lives.